Clinical Trials Logo

Filter by:
NCT ID: NCT04856930 Completed - Clinical trials for Hidradenitis Suppurativa

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa

Start date: July 7, 2021
Phase: Phase 2
Study type: Interventional

Efficacy and Safety of Imsidolimab (ANB019) in Subjects with Hidradenitis Suppurativa

NCT ID: NCT04795557 Completed - Covid19 Clinical Trials

Efficacy of Adaptogens in Patients With Long COVID-19

Start date: April 19, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this clinical trial of a fixed combination of standardized extracts from Rhodiola rosea roots, Schisandra chinensis berry and Eleutherococcus senticosus root (ADAPT-232) in COVID-19 patients is to demonstrate possible efficacy of adjuvant treatment with ADAPT-232 in decreasing the duration of the convalescence, alleviation of fatigue, headache, attention deficit, difficult and rapid respiration, depression, anxiety and other symptoms of Long COVID-19 during rehabilitation period.

NCT ID: NCT04792385 Completed - Safety Clinical Trials

Safety, Compliance and Pharmacokinetics of Estetrol Monohydrate/Drospirenone 15/3 mg in Post-menarchal Female Adolescents

Start date: December 28, 2020
Phase: Phase 3
Study type: Interventional

To evaluate the safety, compliance, and pharmacokinetics profile of estetrol monohydrate (E4) 15 mg combined with drospirenone (DRSP) 3 mg in post-menarchal participants between the age of 12 and 17 years + 2 months.

NCT ID: NCT04775264 Completed - Atrial Fibrillation Clinical Trials

Safety and Feasibility of Atrial Deganglionation as Adjunctive Therapy for AF

Neural-AF
Start date: May 17, 2021
Phase: N/A
Study type: Interventional

A prospective, single arm, multi-center exploratory study of safety and feasibility in the treatment of patients undergoing cardiothoracic surgery.

NCT ID: NCT04772742 Completed - Migraine Clinical Trials

Eptinezumab in Adults With Migraine and Medication Overuse Headache

Sunlight
Start date: February 17, 2021
Phase: Phase 3
Study type: Interventional

This study evaluates the efficacy of eptinezumab to prevent migraine and headache in patients with the combined diagnosis of migraine and medication overuse headache

NCT ID: NCT04761627 Completed - Psoriasis Clinical Trials

A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Start date: March 24, 2021
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate pharmacokinetic similarity, efficacy, safety and immunogenicity of multiple switches between ustekinumab and ABP 654 compared with continued use of ustekinumab in participants with moderate to severe plaque psoriasis.

NCT ID: NCT04758598 Completed - Open Angle Glaucoma Clinical Trials

The Effects of DSLT and SLT on the Corneal Endothelium: A GLAUrious Trial Sub-Study

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

The objective of this study is to compare the long-term (6 months) effects of Direct Selective Laser Trabeculoplasty (DSLT) treatment and SLT (Selective Laser Trabeculoplasty) treatment on corneal endothelial cell counts and corneal thickness.

NCT ID: NCT04740723 Completed - Hypertension Clinical Trials

Evaluation of the Integrated Radio Frequency Denervation System for the Treatment of Hypertension

RADAR
Start date: February 6, 2021
Phase: N/A
Study type: Interventional

The objective of the study is to evaluate the safety of renal denervation using the iRF System and to understand any potential improvement in hypertension.

NCT ID: NCT04735432 Completed - Clinical trials for Generalized Myasthenia Gravis

Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis

ADAPTsc
Start date: February 5, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the Pharmacodynamics (PD), Pharmacokinetics (PK), safety, tolerability, immunogenicity, and clinical efficacy of efgartigimod coformulated with recombinant human hyaluronidase PH20 (rHuPH20) as compared to efgartigimod IV infused in patients with generalized myasthenia gravis (gMG). The study duration is approximately 12 weeks. After screening, patients will be randomized to receive either efgartigimod infusions or efgartigimod PH20 subcutaneously (SC)

NCT ID: NCT04733040 Completed - Glomerulonephritis Clinical Trials

Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE)

NewPLACE
Start date: January 20, 2021
Phase: Phase 2
Study type: Interventional

This 2-arm, multi-center, open-label, parallel-group phase II trial will assess the efficacy, safety and pharmacokinetics/pharmacodynamics of the human antibody MOR202 in subjects with anti-PLA2R antibody-positive membranous nephropathy indicated for immunosuppressive therapy